A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam
Launched by GALDERMA R&D · Feb 16, 2007
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
Same as above.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects must have a clinical diagnosis of moderate to severe plaque psoriasis, defined as 3%-20% of the body surface area involved
- Exclusion Criteria:
- • Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® spray or more than 50 grams per week of Olux® foam
- • Subjects whose psoriasis involves the scalp, face or groin
- • Subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vallejo, California, United States
Saint Louis, Missouri, United States
Patients applied
Trial Officials
Ronald W. Gottschalk, MD
Study Director
Galderma Laboratories, LP
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials